Who Qualifies for Spravato Treatment?

Spravato (esketamine) is FDA-approved for adults with treatment-resistant depression or major depressive disorder with active suicidal ideation. To qualify, patients typically must have tried at least two antidepressants without adequate relief. A licensed provider evaluates medical history, current medications, and risk factors before approving treatment.

Spravato has opened a meaningful new door for people who have not responded to traditional antidepressants. Still, it is not the right fit for everyone. Understanding the qualification criteria helps patients and families approach the conversation with their provider informed and prepared.

What Is Spravato and How Is It Different?

Spravato is a nasal spray form of esketamine, a derivative of ketamine. The FDA approved it in 2019 specifically for adults whose depression has not improved with other treatments.

Unlike standard antidepressants, Spravato works on glutamate receptors in the brain. Most antidepressants target serotonin, dopamine, or norepinephrine pathways. This difference in mechanism is one reason Spravato may work when other medications have not.

It is not a take-home prescription. Spravato must be administered in a certified healthcare setting, with patients monitored for at least two hours after each dose. This requirement exists because of potential side effects including dissociation, dizziness, and elevated blood pressure.

The Two FDA-Approved Indications

Spravato has two distinct approved uses. Each comes with specific qualification criteria.

Treatment-Resistant Depression (TRD)

Treatment-resistant depression applies when a patient has major depressive disorder (MDD) and has not responded adequately to at least two different antidepressant treatments. Those two treatments must have been:

• Different classes of antidepressants
• Used at adequate doses
• Continued for an adequate duration (typically six to eight weeks each)

Simply not tolerating side effects may not meet the threshold. The antidepressants generally need to have failed on effectiveness grounds. A provider reviews the medication history in detail to confirm this.

Major Depressive Disorder with Acute Suicidal Ideation or Behavior (MDSI)

The second approved indication covers adults experiencing MDD with active suicidal ideation or behavior. This use targets patients who need rapid stabilization. Spravato can produce antidepressant effects within hours, which makes it relevant in crisis situations when waiting weeks for a traditional medication to work is not a viable option.

This indication does not require a prior trial of two antidepressants. The acute nature of the situation changes the qualifying criteria.

Medical and Diagnostic Requirements

Confirmed MDD Diagnosis

A formal diagnosis of major depressive disorder is required before Spravato is considered. Providers use structured clinical criteria, typically from the DSM-5, to confirm the diagnosis. Conditions like bipolar disorder, schizophrenia, or other psychotic disorders are not approved indications and can affect eligibility.

Antidepressant Medication History

For TRD candidates, providers document the prior antidepressant trials. This means verifying the medications used, the doses prescribed, and the duration of each trial. Patients often benefit from bringing pharmacy records or prior treatment notes to this evaluation.

Current Oral Antidepressant Requirement

Spravato is not approved as a standalone treatment for TRD. It must be used alongside a current oral antidepressant. If a patient is not currently on an antidepressant, the prescribing provider will address this before starting Spravato.

Who May Not Qualify for Spravato

Spravato is not appropriate for everyone with depression. Certain medical and psychiatric conditions create contraindications or require careful evaluation before proceeding.

Patients who may not qualify include:

• People with a history of aneurysmal vascular disease or arteriovenous malformation
• Those with a history of intracerebral hemorrhage
• Patients with hypersensitivity to esketamine or ketamine
• People with active psychosis or certain unstable psychiatric conditions
• Patients who are pregnant or breastfeeding

Substance use history also factors into evaluation. Spravato carries risks for people with a history of drug abuse or dependence, including ketamine misuse. Providers weigh this carefully, since Spravato itself has abuse potential.

Age is another factor. Spravato is currently approved only for adults. It is not indicated for pediatric or adolescent patients.

The Evaluation and Approval Process

Qualifying for Spravato is not a self-referral process. It requires a clinical evaluation by a trained provider. Here is what that process typically involves.

Initial Consultation

The provider reviews the patient’s full psychiatric history, prior medication trials, current medications, and any relevant medical history. This visit clarifies whether the patient meets TRD or MDSI criteria and whether there are contraindications to treatment.

Risk-Benefit Discussion

Spravato carries real risks. Providers discuss potential side effects including dissociation, nausea, dizziness, and increased blood pressure. The conversation also covers the monitoring requirements and what a typical treatment session looks like.

REMS Program Enrollment

Spravato is only available through the FDA’s Risk Evaluation and Mitigation Strategy (REMS) program. Both the prescribing provider and the treatment facility must be certified. Patients are enrolled in this program before their first dose. This structure exists to ensure proper monitoring and to reduce the risk of serious adverse outcomes.

Insurance Verification

Spravato is expensive without coverage. Most commercial insurance plans and Medicare cover it for qualifying patients, but prior authorization is typically required. The treatment team handles this verification before scheduling the first session.

What Spravato Treatment Looks Like

For patients who qualify, understanding the treatment schedule helps set realistic expectations.

Sessions are usually twice weekly for the first month, then weekly for the second month, then every one to two weeks for maintenance. Each session involves self-administering the nasal spray under supervision, followed by a monitored rest period of at least two hours.

Patients cannot drive on the day of treatment. Arranging transportation is a practical requirement that providers discuss during onboarding.

Response varies. Some patients notice improvement within days. Others take several weeks of consistent treatment. The treating provider monitors progress and adjusts the schedule based on response and tolerability.

Spravato in Southern Utah

Mental Health and Wellness of Southern Utah offers Spravato treatment for qualifying adults in the St. George area and surrounding communities. The practice is a certified Spravato treatment center, which means the facility and providers meet the requirements of the REMS program.

Patients interested in learning whether they qualify can contact the practice directly to schedule an evaluation. The clinical team reviews each patient’s history and works through the qualification criteria during that initial visit.

For patients who have tried multiple antidepressants without relief, this evaluation is often the first conversation that opens a path toward a different kind of treatment.

Frequently Asked Questions

Do I need a referral to be evaluated for Spravato?

A formal referral is not always required, but the process starts with a clinical evaluation. You can contact a certified Spravato provider directly to schedule a consultation. The provider will review your diagnosis and medication history to determine whether you qualify.

Does insurance cover Spravato treatment?

Many major insurance plans, including Medicare, cover Spravato for patients who meet the FDA-approved criteria. Prior authorization is typically required, and coverage varies by plan. The treatment team can assist with the prior authorization process before your first session.

Can Spravato be used with other mental health medications?

Yes. Spravato for TRD is specifically approved for use alongside an oral antidepressant. Your provider will review your current medications to check for interactions and will guide any adjustments needed before starting treatment.

How long does it take for Spravato to work?

Some patients notice improvement within hours or days after their first sessions. For others, meaningful relief develops over several weeks of treatment. Response timelines vary, and the treating provider monitors progress throughout to adjust the schedule as needed.

Is Spravato the same as ketamine infusion therapy?

Spravato and ketamine infusions both work on glutamate receptors, but they are not identical. Spravato is an FDA-approved nasal spray form of esketamine (an enantiomer of ketamine), administered in certified clinical settings. Ketamine infusions use racemic ketamine intravenously. The two have overlapping mechanisms but different approval statuses, delivery methods, and monitoring protocols.

What happens if I have a history of substance use?

Substance use history is reviewed during the evaluation. Spravato has abuse potential, and providers weigh this carefully. A history of substance use does not automatically disqualify someone, but it is a significant factor in the risk-benefit assessment. Your provider will discuss this with you directly.

Reviewed by a licensed psychiatric provider at Mental Health and Wellness of Southern Utah.

This article is for informational purposes only and does not constitute medical advice. Spravato eligibility is determined by a qualified mental health provider based on individual clinical history. Contact a licensed provider for diagnosis and treatment recommendations specific to your situation.